UCLA researchers engineer CAR-T cells to target hard-to-treat solid tumors
UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack and fuel tumor growth.
By equipping CAR-T cells with the ability to block a key tumor-produced protein called VEGF, the researchers gave the engineered immune cells the power not only to attack cancer directly, but also to dismantle the tumor’s defenses and restore the immune system’s ability to fight back.
In preclinical ...